[1]Siebel C, Lendahl U. Notch signaling in development, tissue homeostasis, and disease[J]. Physiol Rev, 2017, 97(4):1235-1294.
[2]Chapman G, Dunwoodie SL. Role of Delta-like-3 in mammalian somitogenesis and vertebral column formation[J]. Adv Exp Med Biol, 2008, 638:95-112.
[3]Dunwoodie SL, Clements M, Sparrow DB, et al. Axial skeletal defects caused by mutation in the spondylocostal dysplasia/pudgy gene Dll3 are associated with disruption of the segmentation clock within the presomitic mesoderm[J]. Development, 2002, 129(7):1795-1806.
[4]Turnpenny PD, Whittock N, Duncan J, et al. Novel mutations in DLL3, a somitogenesis gene encoding a ligand for the Notch signalling pathway, cause a consistent pattern of abnormal vertebral segmentation in spondylocostal dysostosis[J]. J Med Genet, 2003, 40(5):333-339.
[5]Yan S, Ma D, Ji M, et al. Expression profile of Notch-related genes in multidrug resistant K562/ADM cells compared with parental K562 cells[J]. Int J Lab Hematol, 2010, 32(2):150-158.
[6]Maemura K, Yoshikawa H, Yokoyama K, et al. Delta-like 3 is silenced by methylation and induces apoptosis in human hepatocellular carcinoma[J]. Int J Oncol, 2013, 42(3):817-822.
[7]Deng SM, Yan XC, Liang L, et al. The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice[J]. Biochem Biophys Res Commun, 2017, 483(1):488-494.
[8]Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study[J]. Lancet Oncol, 2017, 18(1):42-51.
[9]Gao FL, Liu ShM, Wu JL, et al. The reversal effect on mdr1 gene-mediated multidrug resistance in gastric cancer SGC7901/VCR cells by small interfering RNA [J]. Acta Anatomica Sinica, 2006, 37(1):57-61. (in Chinese)
高福莲, 刘书漫, 吴景兰, 等. 小分子干扰RNA逆转胃癌SGC7901/VCR细胞mdr1介导的多药耐药 [J]. 解剖学报, 2006, 37(1):57-61.
[10]Chufan EE, Sim HM, Ambudkar SV. Molecular basis of the polyspecificity of P-glycoprotein (ABCB1): recent biochemical and structural studies[J]. Adv Cancer Res, 2015, 125:71-96.
[11]Li D, Gale RP, Liu Y, et al. 5’-Triphosphate siRNA targeting MDR1 reverses multi-drug resistance and activates RIG-Ⅰ-induced immune-stimulatory and apoptotic effects against human myeloid leukaemia cells[J]. Leuk Res, 2017, 58:23-30.
[12]Kim HJ, Lee KY, Kim YW, et al. P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement[J]. BMC Cancer, 2015, 15(1):553.
[13]Gu J, Fang X, Hao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery[J]. Biomaterials, 2015, 45:99-114.
[14]Sheng L, Xiong M, Li C, et al. Reversing multidrug-resistant by RNA interference through silencing MDR1 gene in human hepatocellular carcinoma cells subline Bel-7402/ADM[J]. Pathol Oncol Res, 2014, 20(3):541-548.
[15]Zhu CY, Lv YP, Yan DF, et al. Knockdown of MDR1 increases the sensitivity to adriamycin in drug resistant gastric cancer cells[J]. Asian Pac J Cancer Prev, 2013, 14(11):6757-6760.
[16]Ramsay EE,Dilda PJ. Glutathione S-conjugates as prodrugs to target drug-resistant tumors[J]. Front Pharmacol, 2014, 5:181.
[17]Vasieva O. The many faces of glutathione transferase pi[J]. Curr Mol Med, 2011, 11(2):129-139.
[18]Zhao D, Jiang Y, Dong X, et al. Arsenic trioxide reduces drug resistance to adriamycin in leukemic K562/A02 cells via multiple mechanisms[J]. Biomed Pharmacother, 2011, 65(5):354-358.
|